ストックスクリーナーアプリを入手
1,064.74
0.02%
-0.26
プレマーケット:
1067.03
2.29
+0.22%
前日終値:
$1,065.00
開ける：
$1075
24時間の取引高:
2.85M
Relative Volume:
0.93
時価総額：
$949.47B
収益：
$72.25B
当期純損益:
$25.28B
株価収益率:
38.33
EPS:
27.781
ネットキャッシュフロー:
$10.37B
1週間 パフォーマンス:
+4.24%
1か月 パフォーマンス:
+20.45%
6か月 パフォーマンス:
-3.59%
1年 パフォーマンス:
+49.18%
1日の値動き範囲:
$1,060.36
$1,082.00
1週間の範囲:
$1,003.69
$1,082.00
52週間の値動き範囲:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Compare LLY vs JNJ, ABBV, MRK, AZN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,064.74 | 949.70B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.18 | 564.11B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
213.12 | 381.10B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.72 | 302.33B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.19 | 290.06B | 60.48B | 10.40B | 8.05B | 3.3297 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-17 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2026-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-02-20 | 開始されました | Barclays | Overweight |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-12-16 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | 繰り返されました | BofA Securities | Buy |
| 2025-12-15 | 繰り返されました | Goldman | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-11-10 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 繰り返されました | BMO Capital Markets | Outperform |
| 2025-10-14 | アップグレード | Erste Group | Hold → Buy |
| 2025-09-17 | ダウングレード | Berenberg | Buy → Hold |
| 2025-08-27 | アップグレード | HSBC Securities | Reduce → Hold |
| 2025-08-18 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | ダウングレード | Erste Group | Buy → Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-09-13 | 再開されました | Citigroup | Buy |
| 2024-08-12 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-02-21 | ダウングレード | DZ Bank | Buy → Hold |
| 2024-02-16 | 繰り返されました | Morgan Stanley | Overweight |
| 2023-12-21 | ダウングレード | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-20 | 再開されました | UBS | Buy |
| 2023-08-09 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-26 | 繰り返されました | Citigroup | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-24 | 繰り返されました | BofA Securities | Buy |
| 2023-05-24 | 繰り返されました | UBS | Buy |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-15 | ダウングレード | Societe Generale | Hold → Sell |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-09-22 | アップグレード | UBS | Neutral → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-03-10 | 開始されました | Daiwa Securities | Outperform |
| 2022-01-21 | アップグレード | DZ Bank | Hold → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-16 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-16 | 繰り返されました | BofA Securities | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-10-11 | アップグレード | Berenberg | Hold → Buy |
| 2021-09-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-05 | アップグレード | DZ Bank | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-06-24 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2021-01-19 | アップグレード | Mizuho | Neutral → Buy |
| 2020-12-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-09-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-04-21 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2019-12-18 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-04-24 | アップグレード | Edward Jones | Hold → Buy |
| 2019-04-11 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-03-12 | 開始されました | JP Morgan | Overweight |
| 2019-01-23 | 開始されました | UBS | Buy |
| 2018-11-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-10-31 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-10-01 | 繰り返されました | SunTrust | Buy |
| 2018-09-26 | 再開されました | JP Morgan | Overweight |
すべてを表示
Lilly Eli Co (LLY) 最新ニュース
Eli Lilly acquires Novo Holdings-backed Limmatech for USD 780m - medwatch.com
Micron Hits $1 Trillion, Overtakes JPMorgan, Walmart And Eli LillyMicron Technology (NASDAQ:MU) - Benzinga
Key facts: Lilly buys 3 vax for up to $4B; PCSK9↓88% LDL‑C↓62%; BofA up GLP‑1 - TradingView
Lilly Follows Upbeat Trials for Cholesterol Shot with $4B M&A Spree - The Daily Upside
GC Biopharma Sells U.S. Affiliate Curevo to Eli Lilly for 459.9 Billion Won - Businesskorea
Eli Lilly Set to Acquire Curevo, LimmaTech Biologics, and Vaccine Co. for $4 Billion - scanx.trade
Lilly buys three vaccine firms to target dementia and infection preventionCHOSUNBIZ - Chosunbiz
Micron Just Became America's 10th-Most-Valuable Company. Wall Street Says It Could Pass Tesla and Meta Next. - The Motley Fool
How The Eli Lilly (LLY) Narrative Is Evolving With GLP-1 Hopes And Obesity Market Doubts - Yahoo Finance
Eli Lilly Buys 3 Vaccine Companies for $3.8B - Powder & Bulk Solids
GC Green Cross Sells U.S. Affiliate Curevo to Eli Lilly - 아시아경제
Former Metro councilman and pastor accused in 'fraud scheme' to steal $200 million from drug company - News Channel 5 Nashville
Lilly spending nearly $4B to acquire three vaccine developers - Inside INdiana Business
Lilly Is Looking for Its Next Act Beyond the Weight-Loss Boom - Barron's
Lilly to acquire three vaccine developers for up to $3.83 billion By Investing.com - Investing.com Canada
Eli Lilly and Company to acquire 3 vaccine development companies for nearly $4 billion - WTHR
Eli Lilly Expands Vaccine Push With Deals Worth Up To $3.8B - Law360
Eli Lilly acquires three vaccine companies for infectious disease portfolio - Managed Healthcare Executive
Lilly goes on $20 billion buying spree as company seeks next act - The Daily Gazette
What's Going On With Eli Lilly Stock Tuesday?Eli Lilly (NYSE:LLY) - Benzinga
Lilly to buy three vaccine developers for up to $3.8 billion - MSN
Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion - marketscreener.com
Lilly Goes on $20 Billion Buying Spree as Company Seeks Next Act - Yahoo Finance
Lilly Gets Back Into the Vaccine Business With New Deals - marketscreener.com
LLY: Eli Lilly Acquires Three Vaccine Developers for $3.8 Billio - GuruFocus
Eli Lilly targets vaccines market with $3.8B acquisition of three biotech firms - Proactive financial news
Lilly buys three vaccine makers; PCSK9 base editor shows promise - BioWorld News
Early data for heart drug affirm Lilly’s billion-dollar bet on Verve - BioPharma Dive
Lilly dives into vaccine research with 3 biotech buyouts - BioPharma Dive
Eli Lilly spending $3.8 billion to buy vaccine makers - Axios
Healthcare Takeovers Tick Pass $140 Billion After Latest Lilly Spree - Bloomberg.com
Lilly goes on $21B buying spree to build drug pipeline - dailyjournal.net
Lilly to buy three vaccine developers for nearly US$4 billion in infectious disease push - CTV News
Eli Lilly and Co. splashes out $3.8 billion to acquire three companies, aiming to get a head start in the next round of the global vaccine race - 富途牛牛
Eli Lilly announces acquisition of 3 vaccine makers in $4 billion deal - upi.com
Analyst recommendations: Eli Lilly, AutoZone, BP plc, Ferrari, Samsung Electronics… - marketscreener.com
Positive Clinical Data for Eli Lilly's Gene Editing Therapy VERVE-102 - GuruFocus
Eli Lilly Bets Nearly $4 Billion on Vaccines: Is the Weight-Loss Drug Giant’s Next Growth Curve Here? - TradingKey
Lilly Expands Into Vaccines With Three Infectious Disease Acquisitions Worth Up to $3.8 Billion - citybiz
Lilly to Acquire Vaccine Company in $1.55 Billion Bet on Epstein-Barr Vaccine Development - citybiz
Lilly to Acquire Curevo in Deal Focused on Next-Generation Shingles Vaccine - citybiz
Eli Lilly to buy trio of vaccine developers in $3.8bn outlay - Pharmaceutical Technology
Eli Lilly and Co (LLY) Stock Price, Trades & News - GuruFocus
Lilly Agrees to Buy Trio of Vaccine Developers - WSJ
Here’s What the Street is Saying About Eli Lilly and Company (LLY) - Insider Monkey
Eli Lilly (LLY) Acquires Three Vaccine Firms for Nearly $4 Billi - GuruFocus
Eli Lilly's VERVE-102 Shows Promising Results in Early Trial - GuruFocus
Eli Lilly (LLY) Expands Vaccine Portfolio with $4B in Acquisitio - GuruFocus
Eli Lilly (LLY) Expands Infectious Disease R&D Through New Acqui - GuruFocus
Lilly (LLY) to Acquire LimmaTech Biologics for Up to $780 Millio - GuruFocus
Eli Lilly to acquire Curevo, LimmaTech Biologics and Vaccine Company in multibillion dollar bet on infectious - CNBC TV18
Lilly Eli Co (LLY) 財務データ
収益
当期純利益
現金流量
EPS
1.78%
0.09%
大文字化:
|
ボリューム (24 時間):